View Older Stories View More Recent Stories

Dec 3, 2020 08:17AM Genprex to Present at the Benzinga Global Small Cap Conference on December 8
Nov 30, 2020 02:05PM Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Nov 24, 2020 08:16AM Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1
Nov 11, 2020 08:16AM Genprex to Participate in Panel at Life Sciences Summit on November 17
Nov 10, 2020 08:17AM Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD
Oct 30, 2020 08:17AM Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
Oct 29, 2020 08:20AM Genprex (GNPX) Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Oct 29, 2020 08:16AM Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Oct 26, 2020 08:16AM Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
Oct 7, 2020 08:17AM Genprex to Present at Zooming with LD Micro on October 14, 2020
Oct 6, 2020 08:16AM Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
Sep 21, 2020 08:17AM Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
Sep 2, 2020 08:17AM Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs
Aug 26, 2020 08:17AM Genprex to Present at The LD 500 Virtual Conference
Aug 26, 2020 08:17AM Genprex to Present at The LD 500 Virtual Conference
Jul 31, 2020 08:17AM Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020
Jul 30, 2020 08:16AM Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”
Jul 21, 2020 08:17AM National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex
Jun 29, 2020 08:16AM Genprex Added to Russell 3000® Index
Jun 25, 2020 08:18AM Genprex (GNPX) Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Jun 25, 2020 08:17AM Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Jun 24, 2020 08:16AM Genprex CEO to Interview Live on “The Big Biz Show”
Jun 16, 2020 08:17AM Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development
Jun 9, 2020 08:17AM Genprex Scheduled to Join Russell 3000® Index
Jun 8, 2020 08:17AM Genprex to Present at the MoneyShow June Virtual Event
May 28, 2020 08:17AM Genprex (GNPX) Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
May 28, 2020 08:17AM Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
May 5, 2020 08:59AM Genprex (GNPX) Surges After Entering License Agreement with MD Anderson for its TUSC2 Gene Therapy Combo
May 5, 2020 08:17AM Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
May 4, 2020 08:17AM Genprex Issues April 2020 Shareholder Letter
Apr 21, 2020 08:17AM Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations
Mar 24, 2020 08:17AM Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders
Mar 23, 2020 08:17AM Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives
Mar 5, 2020 08:05AM Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview
Mar 4, 2020 08:00AM Genprex to Present at the 2020 LD Micro Virtual Conference
Mar 3, 2020 08:17AM Genprex to Present at the 2020 LD Micro Virtual Conference
Feb 21, 2020 04:15PM Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants
Feb 19, 2020 09:23AM Genprex (GNPX) Prices 5M Shares at $3.50
Feb 19, 2020 09:23AM Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants
Feb 11, 2020 08:17AM Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
Feb 6, 2020 08:24AM Genprex (GNPX) Regains Compliance with Nasdaq Minimum Bid Price Requirement
Feb 6, 2020 08:17AM Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Feb 5, 2020 09:00AM Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)
Feb 3, 2020 08:17AM Genprex to Present at NobleCon16 Investor Conference
Jan 29, 2020 08:18AM Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy
Jan 28, 2020 08:00AM Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering
Jan 23, 2020 09:01AM Genprex (GNPX) Prices 7.62M Share Common Offering at $1.05/Sh
Jan 23, 2020 09:00AM Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market
Jan 21, 2020 08:01AM Genprex (GNPX) Granted FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer
Jan 21, 2020 08:00AM Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer
View More Recent Stories View Older Stories